NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug conjugates (ADCs) today announces that it will present three ...
Shares of Zymeworks (ZYME) are moving higher lately, led by an overall recovery of biotech stocks, and, perhaps, by increased investor interest in the company’s emerging antibody-drug conjugate (‘ADC’ ...
NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced further expansion ...
Sutro Biopharma, Inc. announced a strategic shift in its focus towards its next-generation antibody drug conjugate (ADC) portfolio following a strategic review, reprioritizing its pipeline to ...
SUZHOU, China, May 4, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), announced today that its subsidiary, Levena Biopharma Co., Ltd ...
Merck KGaA has become the latest biopharma to swell its oncology pipeline with further antibody-drug conjugate (ADC) potential this week. The German company has signed up Texas’ Caris Life Sciences ...
Hosted on MSN
Zymeworks outlines capital allocation strategy and expands ADC pipeline while targeting funding through 2027
Patterson stated, "we expect our existing cash resources as of September 30, 2025, when combined with the assumed receipt of certain anticipated regulatory milestones will enable us to fund planned ...
USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally Round led by Venrock Healthcare Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results